Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 31;109(4):djw249.
doi: 10.1093/jnci/djw249. Print 2017 Apr.

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

Catherine S Diefenbach  1 , Joseph M Connors  1 , Jonathan W Friedberg  1 , John P Leonard  1 , Brad S Kahl  1 , Richard F Little  1 , Lawrence Baizer  1 , Andrew M Evens  1 , Richard T Hoppe  1 , Kara M Kelly  1 , Daniel O Persky  1 , Anas Younes  1 , Lale Kostakaglu  1 , Nancy L Bartlett  1
Affiliations
Review

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

Catherine S Diefenbach et al. J Natl Cancer Inst. .

Abstract

The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and potentially practice changing clinical trials. This review from the Hodgkin lymphoma (HL) subcommittee of the CTPM discusses the ongoing clinical challenges in HL, outlines the current standard of care for HL patients from early to advanced stage, and surveys the current science with respect to biomarkers and the landscape of ongoing clinical trials. Finally, we suggest areas of unmet need in HL and elucidate promising therapeutic strategies to guide future HL clinical trials planning across the NCTN.

PubMed Disclaimer

References

    1. Hanly P, Soerjomataram I, Sharp L.. Measuring the societal burden of cancer: The cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer. 2015;1364:E136–E145. - PubMed
    1. National Cancer Institute Surveillance, Epidemiology and End Results Program (SEER). http://seer.cancer.gov/statfacts/html/hodg.html.
    1. Bazzeh F, Rihani R, Howard S, et al. Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988–2005: An analysis of 21 734 Cases. Leuk Lymph. 2010;5112:2198–2207. - PubMed
    1. Evens AM, Hutchings M, Diehl V.. Treatment of Hodgkin lymphoma: The past, present, and future. Nat Clin Pract Oncol. 2008;59:543–556. - PubMed
    1. Koontz MZ, Horning SJ, Balise R, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: The Stanford University experience over three generations of clinical trials. J Clin Oncol. 2013;315:592–598. - PMC - PubMed

MeSH terms

Substances